Golden Ten Data on June 9, Anglikang issued a change announcement, the company’s shares for 2 consecutive trading days closing price deviation of more than 20%, belongs to the abnormal fluctuation of stock trading. The company’s current innovative drug project under development is only ALK-N001, which obtained the drug clinical trial approval notice in April 2025 and is still in the phase I clinical trial stage as of the disclosure date of this announcement. The R&D of innovative drugs has the characteristics of long cycle, large investment and high uncertainty, so investors should pay attention to investment risks.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Anglikan: The only innovative drug project currently under research is ALK-N001.
Golden Ten Data on June 9, Anglikang issued a change announcement, the company’s shares for 2 consecutive trading days closing price deviation of more than 20%, belongs to the abnormal fluctuation of stock trading. The company’s current innovative drug project under development is only ALK-N001, which obtained the drug clinical trial approval notice in April 2025 and is still in the phase I clinical trial stage as of the disclosure date of this announcement. The R&D of innovative drugs has the characteristics of long cycle, large investment and high uncertainty, so investors should pay attention to investment risks.